You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)午後股價跌幅收窄至逾8% 指約百萬人接種未收到血栓報告
阿思達克 04-14 14:50
阿斯利康(AZN.US)及強生(JNJ.US)研發的新冠疫苗先後出現懷疑血栓病例。康希諾生物-B(06185.HK)今日盤中曾低見255.2元一度下挫18.4%,公司中午發自願公告指其與阿斯利康新冠疫苗所使用的黑猩猩腺病毒載體和強生新冠疫苗所使用的26型腺病毒載體不同,康希諾生物午後股價跌幅略為收窄,最新報286.8元下跌8.3%。

康希諾生物中午公布,公司注意到部分媒體有關接種阿斯利康新冠疫苗和強生新冠疫苗後個人出現罕見和嚴重血栓病例有關的報道。公司指,重組新型冠狀病毒疫苗(5型腺病毒載體)(「Ad5-nCoV」)的載體為5型腺病毒,一種常見的感染人的腺病毒,與阿斯利康新冠疫苗所使用的黑猩猩腺病毒載體和強生新冠疫苗所使用的26型腺病毒載體不同。

截至今日中午止,接種Ad5-nCoV的約百萬人中未收到與血栓相關的嚴重不良事件的報告。公司將密切關注相關情況並根據香港聯合交易所有限公司證券上市規則的規定在適當的時候作出進一步的公告。(wl/k)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account